NasdaqGS - Nasdaq Real Time Price USD

PMV Pharmaceuticals, Inc. (PMVP)

0.9000

-0.0600

(-6.25%)

At close: April 8 at 4:00:01 PM EDT

Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing

PMV Pharmaceuticals (PMVP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks last month

PMVP
-6.25%
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific; interim analysis data expected mid-2025 Enrollment commenced in the MD Anderson Cancer Center investigator-initiated Phase 1b study evaluating rezatapopt monotherapy and in combination with azacitidine in patients with relapsed or refrac

GlobeNewswire last month

PMVP
-6.25%
3 US Penny Stocks To Consider In February 2025

As of February 2025, U.S. markets have been experiencing a mixed performance, with the S&P 500 and Nasdaq falling for the fourth consecutive day amid concerns about economic outlook and policy impacts. Despite these challenges, investors often look to penny stocks as a potential area for growth due to their affordability and the unique opportunities they present. While once considered speculative, penny stocks can still offer compelling prospects when backed by strong financials, making them...

Simply Wall St. last month

CCG

CCGWW

PMVP
-6.25%
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings. Oppenheimer 35th

GlobeNewswire last month

PMVP
-6.25%
US Penny Stocks To Watch In January 2025

The U.S. stock market has recently seen a rebound, with investor attention shifting to earnings reports and the Federal Reserve's policy meeting. For those willing to explore beyond large-cap stocks, penny stocks—often representing smaller or emerging companies—can present unique opportunities in today's market landscape. Although the term "penny stocks" might seem outdated, these investments remain relevant as they can offer surprising value and potential for growth when backed by solid...

Simply Wall St. 2 months ago

SGRP

HYFM

PMVP
-6.25%
Discover 3 US Penny Stocks With Market Caps Over $40M

As the U.S. stock market reaches new heights with record closings for the S&P 500 and Nasdaq, investors are exploring diverse opportunities beyond large-cap tech stocks. Penny stocks, while often associated with smaller or newer companies, remain a relevant area for those seeking unique investment possibilities. Despite their vintage-sounding name, these stocks can offer surprising value when backed by strong financials, providing potential for significant returns and stability.

Simply Wall St. 4 months ago

KRON

BWEN

PMVP
-6.25%
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis expected by mid-2025PMV Pharmaceuticals is collaborating with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center to support an investigator-initiated Phase 1b study evaluating rezatapopt monotherapy and in combinatio

GlobeNewswire 4 months ago

PMVP
-6.25%
US Penny Stocks To Consider In October 2024

Major U.S. stock indexes have seen a downturn recently, with the Dow Jones, S&P 500, and Nasdaq Composite all experiencing declines amid rising Treasury yields and mixed earnings reports. Despite these fluctuations, there remains potential in the market for those willing to explore beyond established giants. Penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for growth at attractive price points when backed by strong fundamentals and solid...

Simply Wall St. 5 months ago

PMVP
-6.25%
YALA

MRKR
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial

Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis expected by mid-2025 Dose-limiting toxicities observed in rezatapopt and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) combination arm of Phase 1b PYNNACLE trial; rezatapopt 500 mg once-daily in combination with pe

GlobeNewswire 5 months ago

PMVP
-6.25%
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 6 months ago

PMVP
-6.25%
PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 60% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis from Phase 2 monotherapy expected by mid-2025 Eligibility criteria in ongoing Phase 1b rezatapopt and pembrolizumab combination arm of PYNNACLE trial adjusted to align with Phase 2 TP53 Y220C and KRAS wild-type patient population Cash

GlobeNewswire 7 months ago

PMVP
-6.25%
Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher

PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks 9 months ago

PMVP
-6.25%
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June

PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences in June. Management will also participate in one-on-one investor meetings. Jefferies

GlobeNewswire 10 months ago

PMVP
-6.25%
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. Across all human cancers, TP5

GlobeNewswire 10 months ago

PMVP
-6.25%
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock

Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.

Zacks 10 months ago

ACRV

PMVP
-6.25%
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking oral presentation at 2024 SGO Annual Meeting on Women’s Cancer Cash, cash equivalents, and marketable securities of $213.1 million as of March 31, 2024, providing expected cash runway to end of 2026 PRINCETON, N.J., May 09, 2024

GlobeNewswire 10 months ago

PMVP
-6.25%

Performance Overview

Return	PMVP	S&P 500 (^GSPC)
YTD	-40.40%	-15.28%
1-Year	-42.31%	-4.22%
3-Year	-95.76%	+11.02%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PMV Pharmaceuticals, Inc. (PMVP)

Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

3 US Penny Stocks To Consider In February 2025

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

US Penny Stocks To Watch In January 2025

Discover 3 US Penny Stocks With Market Caps Over $40M

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

US Penny Stocks To Consider In October 2024

PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial

Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

Performance Overview